Baicalin regulates the dopamine system to control the core symptoms of ADHD

Abstract We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depen...

Full description

Bibliographic Details
Main Authors: Rongyi Zhou, Jiaojiao Wang, Xinmin Han, Bingxiang Ma, Haixia Yuan, Yuchen Song
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Molecular Brain
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13041-019-0428-5
_version_ 1818998969809764352
author Rongyi Zhou
Jiaojiao Wang
Xinmin Han
Bingxiang Ma
Haixia Yuan
Yuchen Song
author_facet Rongyi Zhou
Jiaojiao Wang
Xinmin Han
Bingxiang Ma
Haixia Yuan
Yuchen Song
author_sort Rongyi Zhou
collection DOAJ
description Abstract We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depending on the dopamine (DA) deficit theory. In this study, fifty SHRs were randomly divided into five groups: methylphenidate (MPH), baicalin (50 mg/kg, 100 mg/kg, or 150 mg/kg), and saline-treated. Ten Wistar Kyoto (WKY) rats were used as controls. All rats were orally administered the treatment for four weeks. Motor activity, spatial learning and memory ability were assessed with the open-field and Morris water-maze tests. The mRNA and protein levels of tyrosine hydroxylase (TH), vesicular monoamine transporter 2 (VMAT2), synaptosomal-associated protein of molecular mass 25kD (SNAP25) and synataxin 1a in synaptosomes were detected with real-time polymerase chain reaction (PCR) and Western blot. In addition, DA levels were measured in the prefrontal cortex and striatum. The results indicated that both MPH and baicalin at doses of 150 mg/kg and 100 mg/kg significantly decreased the hyperactivity and improved the spatial learning memory deficit in the SHRs and increased the synaptosomal mRNA and protein levels of TH, SNAP25, VMAT2 and synataxin 1a compared with saline treatment. MPH significantly increased DA levels in both the prefrontal cortex (PFC) and striatum, while baicalin significantly increased DA levels only in the striatum. The results of the present study showed that baicalin treatment was effective for controlling the core symptoms of ADHD. Baicalin increased DA levels only in the striatum, which suggested that baicalin may target the striatum. The increased DA levels may partially be attributed to the increased mRNA and protein expression of TH, SNAP25, VMAT2, and syntaxin 1a. Therefore, these results suggested that the pharmacological effects of baicalin were associated with the synthesis, vesicular localization, and release of DA and might be effective in treating ADHD. However, further studies are required to better understand the molecular mechanisms underlying these findings.
first_indexed 2024-12-20T22:09:59Z
format Article
id doaj.art-ae1097157ed44457b20a0add899d8183
institution Directory Open Access Journal
issn 1756-6606
language English
last_indexed 2024-12-20T22:09:59Z
publishDate 2019-02-01
publisher BMC
record_format Article
series Molecular Brain
spelling doaj.art-ae1097157ed44457b20a0add899d81832022-12-21T19:25:11ZengBMCMolecular Brain1756-66062019-02-0112111410.1186/s13041-019-0428-5Baicalin regulates the dopamine system to control the core symptoms of ADHDRongyi Zhou0Jiaojiao Wang1Xinmin Han2Bingxiang Ma3Haixia Yuan4Yuchen Song5The First Affiliated Hospital of Henan University of Chinese MedicineNanjing University of Chinese MedicineNanjing University of Chinese MedicineThe First Affiliated Hospital of Henan University of Chinese MedicineNanjing University of Chinese MedicineNanjing University of Chinese MedicineAbstract We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depending on the dopamine (DA) deficit theory. In this study, fifty SHRs were randomly divided into five groups: methylphenidate (MPH), baicalin (50 mg/kg, 100 mg/kg, or 150 mg/kg), and saline-treated. Ten Wistar Kyoto (WKY) rats were used as controls. All rats were orally administered the treatment for four weeks. Motor activity, spatial learning and memory ability were assessed with the open-field and Morris water-maze tests. The mRNA and protein levels of tyrosine hydroxylase (TH), vesicular monoamine transporter 2 (VMAT2), synaptosomal-associated protein of molecular mass 25kD (SNAP25) and synataxin 1a in synaptosomes were detected with real-time polymerase chain reaction (PCR) and Western blot. In addition, DA levels were measured in the prefrontal cortex and striatum. The results indicated that both MPH and baicalin at doses of 150 mg/kg and 100 mg/kg significantly decreased the hyperactivity and improved the spatial learning memory deficit in the SHRs and increased the synaptosomal mRNA and protein levels of TH, SNAP25, VMAT2 and synataxin 1a compared with saline treatment. MPH significantly increased DA levels in both the prefrontal cortex (PFC) and striatum, while baicalin significantly increased DA levels only in the striatum. The results of the present study showed that baicalin treatment was effective for controlling the core symptoms of ADHD. Baicalin increased DA levels only in the striatum, which suggested that baicalin may target the striatum. The increased DA levels may partially be attributed to the increased mRNA and protein expression of TH, SNAP25, VMAT2, and syntaxin 1a. Therefore, these results suggested that the pharmacological effects of baicalin were associated with the synthesis, vesicular localization, and release of DA and might be effective in treating ADHD. However, further studies are required to better understand the molecular mechanisms underlying these findings.http://link.springer.com/article/10.1186/s13041-019-0428-5BaicalinADHDDopamineSpontaneously hypertensive ratsBehavioral tests
spellingShingle Rongyi Zhou
Jiaojiao Wang
Xinmin Han
Bingxiang Ma
Haixia Yuan
Yuchen Song
Baicalin regulates the dopamine system to control the core symptoms of ADHD
Molecular Brain
Baicalin
ADHD
Dopamine
Spontaneously hypertensive rats
Behavioral tests
title Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_full Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_fullStr Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_full_unstemmed Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_short Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_sort baicalin regulates the dopamine system to control the core symptoms of adhd
topic Baicalin
ADHD
Dopamine
Spontaneously hypertensive rats
Behavioral tests
url http://link.springer.com/article/10.1186/s13041-019-0428-5
work_keys_str_mv AT rongyizhou baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT jiaojiaowang baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT xinminhan baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT bingxiangma baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT haixiayuan baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT yuchensong baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd